Study medication may reduce the recurrence of heart attacks and stroke
Investigators at Beaumont Health System seek volunteers who have had a heart attack for a research study evaluating the effectiveness of a medication that reduces inflammation, called canakinumab.
“The five-year study will look at how treatment with canakinumab may reduce the recurrence of major cardiovascular problems, like heart attacks and stroke,” says Wendy Miller M.D., director, nutrition and preventive medicine research, Beaumont Research Institute and the site’s principal investigator. “In addition, we will be looking at the drug’s safety in patients who’ve experienced a heart attack and have ongoing increased inflammation.”
This nationwide study also will test whether or not canakinumab can increase insulin secretion and sensitivity in study participants with type 2 diabetes.
According to the National Institutes of Health, type 2 diabetes is the most common form of diabetes, accounting for 90 to 95 percent of all Americans diagnosed with this metabolic disorder.
To be eligible for the study, individuals must:
Be 18 years or older,
Have a history of a heart attack and are considered stable,
Have elevated hsCRP; or C-reactive protein, a marker of inflammation and
Be willing to take injections of canakinumab and/or a placebo, a medication with no active ingredients, at week two and then quarterly for the duration of the trial.
The research is conducted at the Beaumont Health Center, 4949 Coolidge Highway, Royal Oak. If a person qualifies, all study-related procedures, tests and study medication will be provided at no cost. Study participants are paid for time and travel for each completed visit.
For more information, including eligibility, contact Beaumont’s Research Institute at (248) 655-5865.